RELAPSED NEUROBLASTOMA
Clinical trials for RELAPSED NEUROBLASTOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED NEUROBLASTOMA trials appear
Sign up with your email to follow new studies for RELAPSED NEUROBLASTOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kids with tough cancers: experimental drug PEEL-224 enters trials
Disease control Recruiting nowThis study tests a new drug called PEEL-224, alone or with standard chemotherapy, in children and young adults whose solid tumors have not responded to treatment or have returned. The first part finds the safest dose, and the second part measures how well the drug combination shr…
Matched conditions: RELAPSED NEUROBLASTOMA
Phase: PHASE1, PHASE2 • Sponsor: Theodore Laetsch • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Double immune attack: new cell combo targets tough childhood cancers
Disease control Recruiting nowThis early-phase study tests a new combination of two different immune cells—NK cells and CAR-T cells—for children and young adults with neuroblastoma or osteosarcoma that has returned or not responded to standard treatments. The NK cells are designed to help the CAR-T cells work…
Matched conditions: RELAPSED NEUROBLASTOMA
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Slowing down immunotherapy infusion may reduce pain in children with Tough-to-Treat neuroblastoma
Disease control Recruiting nowThis phase 1 trial tests whether giving the immunotherapy naxitamab more slowly, alongside standard chemotherapies irinotecan and temozolomide plus sargramostim, can reduce side effects in children with relapsed or refractory neuroblastoma. The study enrolls about 18 patients who…
Matched conditions: RELAPSED NEUROBLASTOMA
Phase: PHASE1 • Sponsor: Steven DuBois, MD • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Engineered immune cells take aim at childhood cancer
Disease control Recruiting nowThis study tests a new treatment for children and young adults with neuroblastoma that has returned or not responded to standard care. The treatment uses specially engineered immune cells from donated cord blood that are designed to recognize and attack two different markers on t…
Matched conditions: RELAPSED NEUROBLASTOMA
Phase: PHASE1, PHASE2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New hope for kids with relapsed neuroblastoma: BEACON2 trial tests drug cocktails
Disease control Recruiting nowThis trial is testing several combinations of existing drugs (dinutuximab beta, bevacizumab, irinotecan, and temozolomide) in children whose neuroblastoma has come back or not responded to standard treatment. About 160 participants will be randomly assigned to different treatment…
Matched conditions: RELAPSED NEUROBLASTOMA
Phase: PHASE1, PHASE2 • Sponsor: University of Birmingham • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Engineered immune cells take on childhood cancer in new trial
Disease control Recruiting nowThis trial tests a new treatment called hALK.CAR T cells for children and young adults with high-risk neuroblastoma that has returned or not responded to standard treatments. The therapy involves taking a patient's own immune cells, engineering them to recognize and attack cancer…
Matched conditions: RELAPSED NEUROBLASTOMA
Phase: PHASE1, PHASE2 • Sponsor: Roberto Chiarle • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Immune cell combo shows promise for tough childhood cancers
Disease control Recruiting nowThis early-phase trial is testing whether giving children with advanced neuroblastoma or osteosarcoma a special type of immune cell (gamma delta T cells) from a healthy donor, along with several standard cancer drugs, is safe and tolerable. The study will enroll 24 children aged …
Matched conditions: RELAPSED NEUROBLASTOMA
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC